Blockchain Registration Transaction Record

United Health Products Awaits FDA Decision on Hemostatic Gauze Study

United Health Products updates on FDA review for CelluSTAT Hemostatic Gauze study, aiming to control bleeding in surgeries. A breakthrough in natural surgical solutions.

This news is significant for healthcare professionals and investors alike, as it highlights the potential for a new, all-natural hemostatic agent to enter the surgical market. The FDA's decision could pave the way for improved patient outcomes in surgeries requiring mild to moderate bleeding control. For investors, the approval could signify a major milestone for United Health Products, potentially impacting its stock value and market position.